

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
INCLUSION OF KINTOR AS A CONSTITUENT OF
HANG SENG COMPOSITE INDEX**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**” or “**Kintor**”, and together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business development of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has been selected by Hang Seng Indexes Company Limited and will be included as a constituent stock of the Hang Seng Composite Index (“**HSCI**”), with effect from September 6, 2021.

The constituents of HSCI have extensive representation in the market. HSCI offers a comprehensive Hong Kong market benchmark that covers the top 95th percentile of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited. Eligible stocks entered the primary election and were then selected based on their rankings in terms of market capitalisation and trading turnover, market representation and other factors. The inclusion of the Company’s stocks in the HSCI indicates that the Company’s stocks are eligible for trading via the Hong Kong Stock Connect.

The Board is of the view that the Company’s inclusion in the market benchmark index represents the capital market’s strong recognition of the Company. It will facilitate the Company to further expand the shareholder base and increase trading liquidity of the Company, resulting in enhanced value of investment and reputation of the Company in the capital market.

By order of the Board

KINTOR PHARMACEUTICAL LIMITED

Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 20 August, 2021

As at the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purposes only*